Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury

Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

(2015) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Efficacy of the β3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials

(2015) Christopher Chapple et al.   EUROPEAN UROLOGY

Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder

(2015) Yoshihisa Matsukawa et al.   UROLOGY

OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury

(2014) Mark Sanford   DRUGS

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

(2014) Christopher R Chapple et al.   INTERNATIONAL JOURNAL OF UROLOGY

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

(2013) Christopher R. Chapple et al.   NEUROUROLOGY AND URODYNAMICS

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

(2011) Thomas M. Kessler et al.   PLoS One

Rehabilitation in Practice: Neurogenic lower urinary tract dysfunction and its management

(2010) Jalesh N Panicker et al.   CLINICAL REHABILITATION

Review of Neurologic Diseases for the Urologist

(2010) Clare J. Fowler et al.   UROLOGIC CLINICS OF NORTH AMERICA

EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction

(2009) Manfred Stöhrer et al.   EUROPEAN UROLOGY